You have been chosen to receive this valuable information.
 
 
View this email in your browser or as plain text Agilent Technologies
   
For Aggregate Analysis | IN BIOPHARMA, THREE QUESTIONS ARE CRITICAL
     
 

Reliably identify the presence of aggregates in characterization of mAbs

Monoclonal antibody (mAb) biotherapeutics have emerged as a critical class of drugs. The efficacy and safety of these biotherapeutics are highly dependent on maintaining a correct molecular structure. The presence of aggregates can lead to undesirable consequences, such as loss of therapeutic activity or even negative physiological effects. Identifying the presence of aggregate proteins in biotherapeutics is crucial.

Nobody understands better than Agilent

A unique non-destructive prescreening method using the Agilent Cary 60 UV-Vis spectrophotometer can quickly, easily, and reliably identify the presence of aggregate proteins.

BE AGILENT SURE

  Learn more  
 
Featured Webinar

Featured Webinar:
How fab are your mAbs?

A complete aggregate analysis workflow for comprehensive, efficient, and reliable characterization of monoclonal antibodies

  Register  
 
New Application Note

New Application Note

Characterization of mAb Aggregation Using an
Agilent Cary 60 UV-Vis
and 1260 Infinity LC

  Learn more  
 
 
     
 
CONNECT WITH AGILENT Facebook   Twitter   LinkedIn   Youtube  
 
     
  Agilent Home  |  About Agilent  |  Legal  |  Subscriptions  |  5301 Stevens Creek Blvd, Santa Clara CA 95051, USA

Agilent is committed to respecting and protecting your privacy. To view the promises that we make to you regarding your personal information, please view Agilent's privacy statement. For questions related to privacy, please send your inquiry to privacy_advocate@agilent.com. If you prefer not to receive promotional e-mails from Agilent in the future, you can unsubscribe at any time. You can also update your e-mail address, contact information, or interest profile to ensure you receive the most relevant information.

© Agilent Technologies, Inc. 2018

  
     
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of LCGC, a UBM publication. You are on the mailing list as %%emailaddress%%.